Portola Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc.

Millennium Pharmaceuticals Limited

Cor Therapeutics, Inc.

Curagen Corporation

Alexion Pharma International Operations Unlimited Company

Pamela B Conley

Genmin Lu

Uma Sinha

Hans-Michael Jantzen

Mark Karbarz

John T Curnutte

Leonard G Presta

Robert M Scarborough

Anjali Pandey

Xiaoming Zhang

David R Phillips

Wolin Huang

Richard August Shimkets

Mukund Mehrotra

David J Julius

Patrick Andre

James E Tomlinson

Kimberly Spytek

Catherine Burgess

Larry J Fretto

Alan M Laibelman

Gregory Coffey

Matthew E Hart

William Grosse

Ramesh Kekuda

James N Topper

Andrew Steele

Hilary Cannon

Edward Szekeres, Jr

Ruey-Bin Yang

Gunther Hollopeter

Vanitha Ramakrishnan-DuBridge

Glenn Michelson

Matthew Birrell

Craig M Grant

The present disclosure relates to antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. In one embodiment, the derivatives described herein lack or have reduced intrinsic coagulant activity.

Antidotes to factor XA inhibitors

The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.

Preparation of factor Xa derivatives

Compositions and methods for treating lymphoma, in particular, T-cell lymphoma and follicular lymphoma, in a human patient are provided. The methods entail administering to the patient an effective amount of cerdulatinib.

Methods for treating lymphoma

The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Antidotes for factor Xa inhibitors and methods of using the same

Antidotes for factor XA inhibitors and methods of using the same

The present invention is directed to pharmaceutical compositions and methods of using combination therapies containing [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea, or a pharmaceutically acceptable salt thereof, for the treatment of thrombosis diseases.

Combination therapy with a compound acting as a platelet ADP receptor inhibitor

Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.

Proteins and nucleic acids encoding same

The present invention includes a novel subtype of the P2-purinergic receptor, referred to as the P2Y receptor. This receptor is expressed selectively in the platelets and brain, and couples to a pertussis toxin-sensitive G protein (Gi). Nucleic acids encoding the receptor and associated screening and therapeutic methods are also disclosed.

Methods of identifying agents that modulate P2Y12 receptor activity

A novel subtype of the P -purinergic receptor, referred to as the P receptor, is disclosed. This receptor is activated by four of its agonists in the following order of specificity: UTP>UDP>ADP>ATP. Nucleic acids encoding the receptor, antibodies that bind to the receptor and associated screening and therapeutic methods also are disclosed.

P2U2 receptor antibodies

Platelet ADP receptor inhibitors

Growing community of inventors

Palo Alto, CA, United States of America

Pamela B Conley